Gout. New opportunities of diagnosis and treatment


Cite item

Full Text

Abstract

In recent yearsincidences of gout has increased. Despite the current diagnostic possibilities, doctors face the difficultiesin establishing the diagnosis. In 2015new criteria of diagnosis of goutwere developed by European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR). In 2016 the EULARexpert group offered the treatment strategy of patients with gout. Main features of the strategy and new researches, revealing the most effective and safest possibilities for gout treatment were laid down in article.

About the authors

S P Yakupova

Associate Professor at Hospital Therapy Department Federal State Budgetary Educational Institution of Higher Education "Kazan Medical University" of the Ministry of Healthcare of the Russian Federation

Email: YakupovaSP@mail.ru
к.м.н., доцент каф. госпитальной терапии Kazan, Russia

References

  1. Neogi T, Jansen T, Dalbeth N et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74(10):1789-98.
  2. Amir Qaseem M.D, PhD M.H.A, Russell P, Harris M.D M.P.H, Mary Ann Forciea M.D; for the Clinical Guidelines Committee of the American College of Physicians. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017; 166(1):58-68.
  3. Richette P et al. 2016 updated EULAR evidence - based recommendations for the management of gout. 2016; 0:1-14.
  4. Nielsen S.M et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017; 76:1870-1882.
  5. Larsson S.C, Carlström M. Coffee consumption and gout: a Mendelian randomisation study. Ann Rheum Dis. 2018 Feb 28. pii: annrheumdis-2018-213055. doi: 10.1136/annrheumdis-2018-213055
  6. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017 Jul 3;15(1):123.
  7. Lytvyn Y, Skrtic M, Yang G.K, Yip P.M, Perkins B.A, Cherney D.Z. Glycosuria - mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015; 308(2): 77-83.
  8. Chen W, Liu X, Ye S. Effects of metformin on blood and urine pro - inflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016; 13:34.
  9. Roughley M.J, Belcher J, Mallen C.D, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta - analysis of observational studies. Arthritis Res Ther. 2015; 17(1):90.
  10. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new - onset chronic kidney disease? A systematic review and meta - analysis based on observational cohort studies. BMC Nephrol. 2014; 15:122.
  11. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter D.J, Choi H. Low - dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014; 73(2):385-90.
  12. Jasvinder A Singh. Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking. Ann Rheum Dis. 2018; 77:317-318.
  13. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 762a33a0-a24f-4ab8-befb-ec80073eb972&t=5a047573-cbf8-4d63-a01d-b9b86afe9824
  14. https://www.drugs.com/drug-interactions/allopurinol-index.html?filter=3&generic_only=
  15. Frampton J.E. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs. 2015; 75(4):427-38.
  16. Chou H.Y, Chen C.B, Cheng C.Y, Chen Y.A, Ng C.Y, Kuo K.L. Febuxostat - associated drug reaction with eosinophilia and systemic symptoms (DRESS). J Clin Pharm Ther. 2015; 40(6):689-692.
  17. https://www.drugs.com/drug-interactions/febuxostat-index.html?filter=3&generic_only=
  18. Roddy E, Packham J, Obrenovic K, Rivett A, Ledingham J.M. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. Rheumatology (Oxford). 2018 Feb 13. doi: 10.1093/rheumatology/kex521
  19. Dalbeth N, Phipps-Green A,Frampton C, Neogi T, Taylor W.J, Merriman T.R. Relationship between serum urate concentrationand clinically evident incident gout: an individualparticipant data analysis. Ann Rheum Dis. 2018;0:1-5. doi: 10.1136/annrheumdis-2017-212288
  20. Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asympto - matic hyperuricemia and chronic kidney disease: Narrative review of a treatmentcontroversial. J Adv Res. 2017; 8(5):555-560.
  21. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double - blind, randomized, placebo - controlled trial. Am J Kidney Dis. 2015; 66: 945-950.
  22. Maria Erika G. Ramirez, Joanne M Bargman. Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review. J Adv Res. 2017 Sep; 8(5): 551-554.
  23. Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y et al.The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 2014; 15: 26.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies